M. Mauri, M. Miniati - Vol. 8, September 2002, Issue 3
Testo Bibliografia Summary Indice
Eterogeneitą dei farmaci antidepressivi: venlafaxina vs
SSRIs.
La metanalisi come strumento discriminante
Antidepressants heterogeneity: venlafaxine vs SSRIs through the lens
of the metanalysis
2 Cassano GB, Dell’Osso L, Frank E, Miniati M, Fagiolini A, Shear K, Pini S, Maser J. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. Affect Disord 1999;54:319-28.
3 Cassano GB, Pini S. A spectrum model for mood disorders: a useful approach in clinical psychiatry in search of an assessment methodology. Epidemiol Psichiatr Soc 2000;9:156-62.
4 Cassano GB, Michelini S, Shear MK, Coli E, Maser JD, Frank E. The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms. Am J Psychiatry 1997;154(6 Suppl):27-38.
5 Javitt DC, Cienfuegos A, Miniati M, Silipo G, Levine J, Allingham BH, Robinson JJ. A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients. Clin Psychiatry 2002;63:585-90.
6 Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature. Arch Gen Psychiatry 1991;48:796-800.
7 Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
8 Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991;27:141-4.
9 Schweizer E, Weise C, Clary C, Fox I, Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991;11:233-6.
10 Samuelian JC, Tatossian A, Hackett D. A andomized double-blind parallel group comparison of venlafaxine and clomipramine in outpatients with major depression. Clinical Neuropharmacology 1992;15(suppl 1):324B.
11 Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993;29:169-74.
12 Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-8.
13 Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106.
14 Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
15 Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-43.
16 Tiller J, Johnson G, O’Sullivan B, Evans L, George T, Yetman R. Venlafaxine: A Long-Term study. Clin Neuropharmacol 1992;14(suppl 1):342B.
17 Magni G, Hackett D. An Open Label evaluation of the Long-Term safety and clinical acceptability of venlafaxine in depressed patients. Clin Neuropharmacol 1992;15(suppl 1):323B.
18 Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994;14:322-9.
19 Rudolph R, Entsuah R., Derivan A. A low relapse rate confirms the long-term efficacy of venlafaxine in the treatment of major depression. Neuropsychopharmacol 1994;suppl 10:105S.
20 Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-23.
21 Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-22.
22 Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171-81.
23 Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-8.
24 Salinas E, for the Venlafaxine XR 367 Study Group. Once daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 1997;42(suppl 1):244S.
25 Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry 1999;60(Suppl 4):23-31; discussion 32.